The monoclonal antibody against interleukin (IL)-6, called PF-04236921, was found to be efficient at reducing severe flares in systemic lupus erythematosus (SLE) patients — particularly in those with high disease activity — when administered at a 10 mg dose. The study, “Efficacy and safety of an interleukin 6 monoclonal antibody for…
During the recent Analyst Day event in New York, Xencor highlighted its lead candidate to treat systemic lupus erythematosus (SLE), now in Phase 2 clinical testing, and other potential treatments advancing in development. “We believe our flexible bispecific oncology platform has substantial potential. Our programs are built on a novel XmAb Fc…
Pregnant women with systemic lupus erythematosus (SLE) carry higher risks for adverse maternal and fetus outcomes according to a recent study. The study, “What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLE,” was published in the…
The Alliance for Children’s Therapeutics presented positive results from an early study of KPI Therapeutics/Kineta’s lead drug candidate, dalazatide, as a possible treatment for children and teenagers with lupus nephritis. The data were given at the recent European League Against Rheumatism’s 17th Annual Congress in London. A key finding was that “patients with…
Immuno-molecular profiling of systemic lupus erythematosus (SLE) patients has uncovered a personalized molecular signature underlying disease activity that may help scientists develop new tailored therapeutics. The study, “Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients,” was recently published in the journal Cell. SLE, which predominantly affects young women, is…
Defects that disrupt the digestion of dead cells can result in a lupus-like autoimmune disorder, according to a study titled “Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells” and recently published in the journal Nature by scientists at St. Jude Children’s Research Hospital.
Patients with systemic lupus erythematosus (SLE) showed significant improvements and decreased disease severity when treated with a combined therapy of belimumab and standard of care measures for up to 24 months, according to results of a two-year study. The study, “Response to belimumab among patients with systemic…
In systemic lupus erythematosus (SLE) patients, intestinal dysbiosis is associated with activation of pro-inflammatory cells. As such, rescuing gut microbiota with beneficial bacteria strains improves patients’ inflammatory profile, according to a study entitled “Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients”…
Pulmonary arterial hypertension (PAH) is a prevalent comorbid factor in systemic lupus erythematosus (SLE) patients, significantly increasing mortality outcomes. This is the conclusion of a recent review titled “Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis,” published in the journal…
A recent study found it is possible to distinguish systemic lupus erythematosus (SLE) patients from those with primary fibromyalgia (FM), with complete specificity, using a new test measuring the levels of abundant proteins in circulation. The study, “Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound…